Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Airs ‘Concerns’ Over IP Barriers

US Agency’s Patent Concerns Include Thickets, Product Hopping And Evergreening

Executive Summary

Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’

You may also be interested in...



Senators Slam FDA And PTO For Patent ‘Oversight Gaps’

A “lack of co-ordination” between the US FDA and PTO has allowed patent thickets to grow via the granting of flawed patents that do not meet legal requirements, senators Maggie Hassan and Bill Cassidy have complained.

Amgen Urges Balance In US Biosimilars Policy

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

Still ‘Work To Be Done’ After Ranibizumab Approval, Says Samsung Bioepis

Samsung Bioepis recently broke new ground with the first US approval for a biosimilar with ophthalmic indications. But, senior vice-president and development division leader Kyung-Ah Kim tells Generics Bulletin, there remains work to be done to ensure that ophthalmic biosimilars can meet their full potential.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel